Thank You! Your Ebook Is READY!

We've emailed you a link to download your eBook “The Complete Guide to Identifying Record-Breaking Trades." You can also scroll to the bottom of this page to click to download straight from here.

P.S. I just published my latest white-paper that I'd like to share with you...it's below, and it's eye opening.


Thompson:
This Biotech Has CHANGED
The Medical Marijuana Industry Forever...Period.


J. Daryl Thompson  
 

The first question you’re asking yourself is,

“Why is the DEA involved in a biotech stock?"

It’s simple...they have given their RARE stamp of approval for this one company to process a massive amount of Cannabis -- more specifically the cannabinoids -- in order to manufacture a medicine delivery system that is 100% patented, safe, and actually solves the biggest problem that medical marijuana is facing.

Yes, the DEA has fully vetting ONE company and their unique process and has given them the stamp of approval to develop their new cannabinoids delivery system.

It’s the DELIVERY SYSTEM That Has Investors’ Attention

In 2015 the researchers at Vitality BioPharma (VBIO) discovered a unique and patented way to bind a plant’s natural sugars (called glycosides) with molecules from other plants.

With Cannabis being all the rage, their research team went to work and were able to bond glycosides to cannabinoids, the chemical compounds found in Cannabis.

After careful analysis, they knew they had come across something more valuable to the medical, pharmaceutical and marijuana industry than ever before.

What they discovered was a new class of drugs they dubbed “cannabosides.” These revolutionary compounds overcome one of the main obstacles to using Cannabis compounds to fight pain and disease: getting HIGH. This is an incredible breakthrough.

While there are literally hundreds of laboratory tests and clinical trials showing that cannabinoids have powerful medicinal properties, these potent natural healing compounds have one significant drawback to FDA and DEA approval...everyone gets high.

You see, an effective dosage of cannabinoids often makes patients ‘under the influence’ which adversely affects patients’ functions more than the medical issue that the cannabinoids often solves.

Enter VITALITY BIOPHARMA and their new delivery system

Patients who are initially delighted by the relief cannabinoids provide become dismayed when the side effects kick in, causing them to discontinue treatment. (This is exactly what happened in a recent clinical trial conducted by GW Pharmaceuticals, one of the few other companies conducting Cannabis-based research.)

The new class of Cannabis-based drugs developed by Vitality BioPharma overcomes the BIGGEST problem patients deal with.

These revolutionary drugs work by allowing cannabinoids to “ride along” with stevia molecules and travel undigested through the body until they’re released at specific targeted sites. Because the cannabinoids don’t enter the bloodstream as they would if they were ingested without being bonded to a glycoside, there are no psychoactive side effects.

The patient receives a dose high enough to provide therapeutic results, but he or she doesn’t get “high” or “stoned” in the process.

Vitality BioPharma (VBIO) has harnessed the healing power of Cannabis, without the psychoactive side effects, by combining cannabinoids with glycosides from the stevia plant.

One Company Disrupting a $69,300,000,000 Market

Countless hours of research has been done on the healing effects of cannabinoids:

Use of Cannabinoids for Spasticity and Pain Management in MS (1)

The Effect of Medicinal Cannabis on Pain and Quality-of-Life Outcomes in Chronic Pain (2)

Medical Cannabis Use Is Associated With Decreased Opiate Medication Use in a Retrospective Cross-Sectional Survey of Patients With Chronic (3)

But what they all come to the same conclusion:

  1. Cannabinoids are an effective, safe, and proven alternative medical application for: Gastrointestinal disorders, C. difficile (“superbug”) infections, Colorectal Cancer, Multiple Sclerosis, Epilepsy, Schizophrenia, Huntington’s Disease, and as a general pain relief (as a replacement for opioid-based painkillers).


  1. The dosages needed to be considered ‘helpful’ or therapeutic often leave patient suffering from the psychedelic effects.

In fact, all those industries have a combined annual market value of 69.3 BILLION dollars...and VBIO is the only stock poised to make a significant mathematical dent...

LET’S TAKE A LOOK AT THE HARD NUMBERS OF THE LUCRATIVE MARKET THAT VITALITY IS ABOUT TO CHANGE:

Vitality Focuses on GUT HEALTH

According to the Centers for Disease Control and Prevention, as of 2015 an estimated 3 million U.S. adults reported being diagnosed with inflammatory bowel diseases (IBD), either Crohn’s disease or ulcerative colitis. (4)

And a recent medical journal article warned that “IBD is increasing worldwide and has become a global emergence disease.” (5)

While it’s unclear exactly how many people suffer from IBD worldwide, it’s safe to say that that these diseases make life unbearable for untold millions. Most people suffering from these terrible afflictions are diagnosed before age 30, and require treatment for the rest of their life.

Some IBD patients spend their entire life on medications that do little to ease their pain, much less cure the disease. The truly unlucky ones (up to 75% of patients) are forced to undergo surgeries, including colectomies and colostomies.

Unfortunately, that treatment consists of taking medications that do little to stop the pain, much less cure the underlying disease. And the cost of treatment is astronomical. Patients currently spend a mind-boggling $8.5 billion on IBD drugs each year. And that’s forecast to grow to $9.5 billion by 2020. (6)

Ending Superbug Infections

Vitality BioPharma (VBIO) also has their drug “VXB-210” in studies for the treatment of so-called “superbug” infections caused by an extremely nasty bacterium called Clostridium difficile (klos-TRID-e-um dif-uh-SEEL). C. difficile is both extremely virulent and extremely difficult to kill. It affects an estimated half million Americans each year, causing symptoms ranging from diarrhea to life-threatening inflammation of the colon. (7)

In a press release dated May 10, 2017, VBIO announced that it had filed for patent protection on the use of one of its cannabosides (presumably VXB-210) for the treatment of infections caused by Clostridium difficile and other ‘superbug’ pathogens.

There are half a dozen current treatment options for C. difficile infections, ranging in cost from $1,300 to $2,600. Assuming an average cost of $2,000 and half a million cases a year (in the U.S. alone), we’re looking at an annual market worth half a billion dollars ($500,000,000). (8)


Globally Vitality BioPharma is poised to quickly take market share out of that industry!

Attacking Colon Cancer Cells

The company has also announced the results of pre-clinical studies showing that one of its cannabosides is effective in the treatment of “multiple colon cancer cell types".

According to the American Cancer Society, colon cancer kills over 50,000 people in the U.S. every year, making it the third leading cause of cancer-related death. (9)

The National Institute of Health estimates that treatment costs will reach $17.4 billion within the next two years. (10)

Again, securing just 10% of this market, would provide the company with $1.7 billion of annual revenue.

The List Continues to GROW

As of publication, Vitality BioPharma (VBIO) has identified and obtained protection for almost 200 cannabinoid/glycoside combinations that appear to have medicinal value. Only about 20 of those, thus far, have been used to create actual drugs.

There’s so much research in the pipeline that the amount of drugs that VBIO could bring to market may be in the HUNDREDS.

The company could be a named mentioned with Pitzer, Perdue, and Johnson & Johnson. A GLOBAL player that came about from their research that’s leading towards the solution to problems for millions of patients, and solving the problem that the FDA and DEA had with the entire medical marijuana industry!

The Team Leading The Movement

In my recently published ebook, I list several key factors that helped medical stocks explode...one of the biggest was the TEAM behind the company. The leadership, research, and depth are factors about which investors take note. Vitality BioPharma’s team (below) have this “it” factor.

10 Keys For Massive Success (History Lesson)

In my 25 years of trading and research I’ve discovered that there are 10 KEYS to massive stock success...short term and long term. These I cover in my ebook, but suffice it to say that when they ALL align then the market truly has the potential to deliver a trading opportunity like none other.

UPDATE: VBIO has hit ALL 10 KEYS...

  • Market Potential
  • Experienced Management
  • Pivot Start-up
  • Pipeline
  • Elasticity
  • Orphan
  • Drug Designation
  • Scientific Stability
  • Prodrugs
  • Patent and Process Protection 
  • Phase 2 & 3 Winners

But what’s so captivating about VBIO is that it doesn’t just have one, or a couple of these key factors, it brings home all 10!!! Potentially making VBIO the medical stock game changer on the market right now. Frankly, if society didn’t still have to deal with the past stigma of using CBD/THC in the medical field, cannabinoids would be heralded as the biggest medical breakthrough of this generation. VBIO has met both of these challenges and changed the whole dynamic of the industry by unlocking the medicinal potential of CBD, while eliminating all the negative side effects.

Having all 10 of these key factors locks-in mega profit potential for investors. VB100 & VB210 has been shown to treat a multitude of illnesses and has shown to be a safe alternative and more effective than other treatments currently available. They are leading the industry developing new compounds and protecting their IP. Knowing all this takes research and industrial knowledge that takes time to consume and mentally digest. However, one thing an investor cannot control is time. When is the best time to invest in a biopharma company? What has happened over time?

This is what makes VBIO’s cannabinoid pharmaceuticals unique and sets them apart from every other CBD pharma on the market or currently undergoing clinical trials. VBIO holds the patents to their own compounds and has continued to show increased safety and efficacy upon entering phase II trials with VB210 and VB100 in 2018.

And as the market continues to change we will see more and more Cannabis products and services try to make a dent in the medical niche...the issue they will face is timing.

First and BEST to market often dominate.

The rest are just picking up scraps.


Don’t forget to follow the 10 Keys For Massive Success, laid out in my new ebook, that will help you discover for yourself how to make wise investments in the pharma/biotech niche.

6. Global Inflammatory Bowel Diseases (IBD) Drug Market Forecast 2017-2027; retrieved electronically from https://www.visiongain.com/Report/1830/Global-Inflammatory-Bowel-Diseases-(IBD)-Drug-Mark et-Forecast-2017-2027

7. https://www.mayoclinic.org/diseases-conditions/c-difficile/symptoms-causes/syc-20351691

8. Lutz, R. What is the Most Cost Effective C. difficile Treatment? MD Magazine. Retrieved electronically from http://www.mdmag.com/medical-news/what-is-the-most-cost-effective-c-difficile-treatment

9. https://www.cancer.org/cancer/colon-rectal-cancer/about/key-statistics.html

10. National Institute of Health cost projection for 2020 retrieved electronically from https://costprojections.cancer.gov/expenditures.html

Thank You! Your Ebook Is READY!

Start Reading “The Complete Guide to Identifying Record-Breaking Trades”

You’ve taken a GREAT first step towards some amazing trading opportunities and I’m so grateful that you’ve given me the chance to share MY knowledge with YOU!

Daryl Thompson

P.S. I just published my latest white paper that I’d like to share with you...it’s below and it’s eye opening.

Learn to Find and Trade The Simple Keys That Record-Breaking Stocks Have In Common For Major Profits

The Complete Guide To Identifying Record-Breaking Trades.

Thank You! Your Ebook Is READY!

We've emailed you a link to download your eBook “The Complete Guide to Identifying Record-Breaking Trades." You can also scroll to the bottom of this page to click to download straight from here.

P.S. I just published my latest white-paper that I'd like to share with you...it's below, and it's eye opening.

The Complete Guide To Identifying Record-Breaking Trades.

Thank You! Your Ebook Is READY!

We've emailed you a link to download your eBook “The Complete Guide to Identifying Record-Breaking Trades." You can also scroll to the bottom of this page to click to download straight from here.

P.S. I just published my latest white-paper that I'd like to share with you...it's below, and it's eye opening.


The DEA Has Allowed This Biotech To CHANGE
 The Medical Marijuana Industry Forever...Period.

J. Daryl Thompson  
 

The first question you’re asking yourself is,

“Why is the DEA involved in a biotech stock?"

It’s simple...they have given their RARE stamp of approval for this one 

company to process a massive amount of Cannabis -- more specifically the cannabinoids -- in order to manufacture a medicine delivery system that is 100% patented, safe, and actually solves the biggest problem that medical marijuana is facing.

Yes, the DEA has fully vetting ONE company and their unique process and has given them the stamp of approval to develop their new cannabinoids delivery system.

It’s the DELIVERY SYSTEM That Has Investors’ Attention

In 2015 the researchers at Vitality BioPharma (VBIO) discovered a unique and patented way to bind a plant’s natural sugars (called glycosides) with molecules from other plants.

With Cannabis being all the rage, their research team went to work and were able to bond glycosides to cannabinoids, the chemical compounds found in Cannabis.

After careful analysis, they knew they had come across something more valuable to the medical, pharmaceutical and marijuana industry than ever before.

What they discovered was a new class of drugs they dubbed “cannabosides.” These revolutionary compounds overcome one of the main obstacles to using Cannabis compounds to fight pain and disease: getting HIGH. This is an incredible breakthrough.

While there are literally hundreds of laboratory tests and clinical trials showing that cannabinoids have powerful medicinal properties, these potent natural healing compounds have one significant drawback to FDA and DEA approval...everyone gets high.

You see, an effective dosage of cannabinoids often makes patients ‘under the influence’ which adversely affects patients’ functions more than the medical issue that the cannabinoids often solves.

Enter VITALITY BIOPHARMA and their new delivery system

Patients who are initially delighted by the relief cannabinoids provide become dismayed when the side 

effects kick in, causing them to discontinue treatment. (This is exactly what happened in a recent clinical trial conducted by GW Pharmaceuticals, one of the few other companies conducting Cannabis-based research.)

The new class of Cannabis-based drugs developed by Vitality BioPharma (VBIO) overcomes the BIGGEST problem patients deal with.

These revolutionary drugs work by allowing cannabinoids to “ride along” with stevia molecules and travel undigested through the body until they’re released at specific targeted sites. Because the cannabinoids don’t enter the bloodstream as they would if they were ingested without being bonded to a glycoside, there are no psychoactive side effects.

The patient receives a dose high enough to provide therapeutic results, but he or she doesn’t get “high” or “stoned” in the process.


Vitality BioPharma has harnessed the healing power of Cannabis, without the psychoactive side effects, by combining cannabinoids with glycosides from the stevia plant.

One Company Disrupting a $69,300,000,000 Market

Countless hours of research has been done on the healing effects of cannabinoids:

Use of Cannabinoids for Spasticity and Pain Management in MS (1)

The Effect of Medicinal Cannabis on Pain and Quality-of-Life Outcomes in Chronic Pain​ (2)

Medical Cannabis Use Is Associated With Decreased Opiate Medication Use in a Retrospective Cross-Sectional Survey of Patients With Chronic (3)

But what they all come to the same conclusion:

1. Cannabinoids are an effective, safe, and proven alternative medical application for: Gastrointestinal disorders, C. difficile (“superbug”) infections, Colorectal Cancer, Multiple Sclerosis, Epilepsy, Schizophrenia, Huntington’s Disease, and as a general pain relief (as a replacement for opioid-based painkillers).

2. The dosages needed to be considered ‘helpful’ or therapeutic often leave patient suffering from the psychedelic effects.

In fact, all those industries have a combined annual market value of 69.3 BILLION dollars...and VBIO is the only stock poised to make a significant mathematical dent...

LET’S TAKE A LOOK AT THE HARD NUMBERS OF THE LUCRATIVE MARKET THAT VITALITY IS ABOUT TO CHANGE:

Vitality Focuses on GUT HEALTH

According to the Centers for Disease Control and Prevention, as of 2015 an estimated 3 million U.S. adults reported being diagnosed with inflammatory bowel diseases (IBD), either Crohn’s disease or ulcerative colitis. (4)

And a recent medical journal article warned that “IBD is increasing worldwide and has become a global emergence disease.” (5)

While it’s unclear exactly how many people suffer from IBD worldwide, it’s safe to say that that these diseases make life unbearable for untold millions. Most people suffering from these terrible afflictions are diagnosed before age 30, and require treatment for the rest of their life. 

Some IBD patients spend their entire life on medications that do little to ease their pain, much less cure the disease. The truly unlucky ones (up to 75% of patients) are forced to undergo surgeries, including colectomies and colostomies.

Unfortunately, that treatment consists of taking medications that do little to stop the pain, much less cure the underlying disease. And the cost of treatment is astronomical. Patients currently spend a mind-boggling $8.5 billion on IBD drugs each year. And that’s forecast to grow to $9.5 billion by 2020. (6)

Ending Superbug Infections

Vitality BioPharma (VBIO) also has their drug “VXB-210” in studies for the treatment of so-called “superbug” infections caused by an extremely nasty bacterium called Clostridium difficile (klos-TRID-e-um dif-uh-SEEL). C. difficile is both extremely virulent and extremely difficult to kill. It affects an estimated half million Americans each year, causing symptoms ranging from diarrhea to life-threatening inflammation of the colon. (7)

In a press release dated May 10, 2017, VBIO announced that it had filed for patent protection on the use of one of its cannabosides (presumably VXB-210) for the treatment of infections caused by Clostridium difficile and other ‘superbug’ pathogens.

There are half a dozen current treatment options for C. difficile infections, ranging in cost from $1,300 to $2,600. Assuming an average cost of $2,000 and half a million cases a year (in the U.S. alone), we’re looking at an annual market worth half a billion dollars ($500,000,000). (8)

Globally Vitality BioPharma is poised to quickly take market share out of that industry!

Attacking Colon Cancer Cells

The company has also announced the results of pre-clinical studies showing that one of its cannabosides is effective in the treatment of “multiple colon cancer cell types".

According to the American Cancer Society, colon cancer kills over 50,000 people in the U.S. every year, making it the third leading cause of cancer-related death. (9)

The National Institute of Health estimates that treatment costs will reach $17.4 billion within the next two years. (10) 

Again, securing just 10% of this market, would provide the company with $1.7 billion of annual revenue.

The List Continues to GROW

As of publication, Vitality BioPharma (VBIO) has identified and obtained protection for almost 200 cannabinoid/glycoside combinations that appear to have medicinal value. Only about 20 of those, thus far, have been used to create actual drugs.

There’s so much research in the pipeline that the amount of drugs that VBIO could bring to market may be in the HUNDREDS.

The company could be a named mentioned with Pitzer, Perdue, and Johnson & Johnson. A GLOBAL player that came about from their research that’s leading towards the solution to problems for millions of patients, and solving the problem that the FDA and DEA had with the entire medical marijuana industry!

The Team Leading The Movement

In my recently published ebook, I list several key factors that helped medical stocks explode...one of the biggest was the TEAM behind the company. The leadership, research, and depth are factors about which investors take note. Vitality BioPharma’s team (below) have this “it” factor.

10 Keys For Massive Success (History Lesson)

In my 25 years of trading and research I’ve discovered that there are 10 KEYS to massive stock success...short term and long term. These I cover in my ebook, but suffice it to say that when they ALL align then the market truly has the potential to deliver a trading opportunity like none other.

UPDATE: VBIO has hit ALL 10 KEYS...

  • Market Potential
  • Experienced Management
  • Pivot Start-up
  • Pipeline
  • Elasticity
  • Orphan Drug Designation
  • Scientific Stability
  • Prodrugs
  • Patent and Process Protection 
  • Phase 2 & 3 Winners

But what’s so captivating about VBIO is that it doesn’t just have one, or a couple of these key factors, it brings home all 10!!! Potentially making VBIO the medical stock game changer on the market right now. Frankly, if society didn’t still have to deal with the past stigma of using CBD/THC in the medical field, cannabinoids would be heralded as the biggest medical breakthrough of this generation. 

VBIO has met both of these challenges and changed the whole dynamic of the industry by unlocking the medicinal potential of CBD, while eliminating all the negative side effects.

Having all 10 of these key factors locks-in mega profit potential for investors. VB100 & VB210 has been shown to treat a multitude of illnesses and has shown to be a safe alternative and more effective than other treatments currently available. They are leading the industry developing new compounds and protecting their IP. Knowing all this takes research and industrial knowledge that takes time to consume and mentally digest. However, one thing an investor cannot control is time. When is the best time to invest in a biopharma company? What has happened over time?

This is what makes VBIO’s cannabinoid pharmaceuticals unique and sets them apart from every other CBD pharma on the market or currently undergoing clinical trials. VBIO holds the patents to their own compounds and has continued to show increased safety and efficacy upon entering phase II trials with VB210 and VB100 in 2018.

And as the market continues to change we will see more and more Cannabis products and services try to make a dent in the medical niche...the issue they will face is timing.

First and BEST to market often dominate.

The rest are just picking up scraps.

Don’t forget to follow the 10 Keys For Massive Success, laid out in my new ebook, that will help you discover for yourself how to make wise investments in the pharma/biotech niche.

6. Global Inflammatory Bowel Diseases (IBD) Drug Market Forecast 2017-2027; retrieved electronically from https://www.visiongain.com/Report/1830/Global-Inflammatory-Bowel-Diseases-(IBD)-Drug-Mark et-Forecast-2017-2027

7. https://www.mayoclinic.org/diseases-conditions/c-difficile/symptoms-causes/syc-20351691

8. Lutz, R. What is the Most Cost Effective C. difficile Treatment? MD Magazine. Retrieved electronically from http://www.mdmag.com/medical-news/what-is-the-most-cost-effective-c-difficile-treatment

9. https://www.cancer.org/cancer/colon-rectal-cancer/about/key-statistics.html

10. National Institute of Health cost projection for 2020 retrieved electronically from https://costprojections.cancer.gov/expenditures.html


The DEA Has Allowed This Biotech To CHANGE  
  The Medical Marijuana Industry Forever...Period.

J. Daryl Thompson  
 

The first question you’re asking yourself is,

“Why is the DEA involved in a biotech stock?"

It’s simple...they have given their RARE stamp of approval for this one company to process a massive amount of Cannabis -- more specifically the cannabinoids -- in order to manufacture a medicine delivery system that is 100% patented, safe, and actually solves the biggest problem that medical marijuana is facing.

Yes, the DEA has fully vetting ONE company and their unique process and has given them the stamp of approval to develop their new cannabinoids delivery system.

It’s the DELIVERY SYSTEM That Has Investors’ Attention

In 2015 the researchers at Vitality BioPharma (VBIO) discovered a unique and patented way to bind a plant’s natural sugars (called glycosides) with molecules from other plants.

With Cannabis being all the rage, their research team went to work and were able to bond glycosides to cannabinoids, the chemical compounds found in Cannabis.

After careful analysis, they knew they had come across something more valuable to the medical, pharmaceutical and marijuana industry than ever before.

What they discovered was a new class of drugs they dubbed “cannabosides.” These revolutionary compounds overcome one of the main obstacles to using Cannabis compounds to fight pain and disease: getting HIGH. This is an incredible breakthrough.

While there are literally hundreds of laboratory tests and clinical trials showing that cannabinoids have powerful medicinal properties, these potent natural healing compounds have one significant drawback to FDA and DEA approval...everyone gets high.

You see, an effective dosage of cannabinoids often makes patients ‘under the influence’ which adversely affects patients’ functions more than the medical issue that the cannabinoids often solves.

Enter VITALITY BIOPHARMA and their new delivery system

Patients who are initially delighted by the relief cannabinoids provide become dismayed when the side effects kick in, causing them to discontinue treatment. (This is exactly what happened in a recent clinical trial conducted by GW Pharmaceuticals, one of the few other companies conducting Cannabis-based research.)

The new class of Cannabis-based drugs developed by Vitality BioPharma (VBIO) overcomes the BIGGEST problem patients deal with.

These revolutionary drugs work by allowing cannabinoids to “ride along” with stevia molecules and travel undigested through the body until they’re released at specific targeted sites. Because the cannabinoids don’t enter the bloodstream as they would if they were ingested without being bonded to a glycoside, there are no psychoactive side effects.

The patient receives a dose high enough to provide therapeutic results, but he or she doesn’t get “high” or “stoned” in the process.

Vitality BioPharma has harnessed the healing power of Cannabis, without the psychoactive side effects, by combining cannabinoids with glycosides from the stevia plant.

One Company Disrupting a $69,300,000,000 Market


Countless hours of research has been done on the healing effects of cannabinoids:

Use of Cannabinoids for Spasticity and Pain Management in MS (1)

The Effect of Medicinal Cannabis on Pain and Quality-of-Life Outcomes in Chronic Pain​ (2)

Medical Cannabis Use Is Associated With Decreased Opiate Medication Use in a Retrospective Cross-Sectional Survey of Patients With Chronic (3)

But what they all come to the same conclusion:

  1. Cannabinoids are an effective, safe, and proven alternative medical application for: Gastrointestinal disorders, C. difficile (“superbug”) infections, Colorectal Cancer, Multiple Sclerosis, Epilepsy, Schizophrenia, Huntington’s Disease, and as a general pain relief (as a replacement for opioid-based painkillers).


  1. The dosages needed to be considered ‘helpful’ or therapeutic often leave patient suffering from the psychedelic effects.

LET’S TAKE A LOOK AT THE HARD NUMBERS OF THE LUCRATIVE MARKET THAT VITALITY IS ABOUT TO CHANGE:

Vitality Focuses on GUT HEALTH

According to the Centers for Disease Control and Prevention, as of 2015 an estimated 3 million U.S. adults reported being diagnosed with inflammatory bowel diseases (IBD), either Crohn’s disease or ulcerative colitis. (4)

And a recent medical journal article warned that “IBD is increasing worldwide and has become a global emergence disease.” (5)

While it’s unclear exactly how many people suffer from IBD worldwide, it’s safe to say that that these diseases make life unbearable for untold millions. Most people suffering from these terrible afflictions are diagnosed before age 30, and require treatment for the rest of their life. 

Some IBD patients spend their entire life on medications that do little to ease their pain, much less cure the disease. The truly unlucky ones (up to 75% of patients) are forced to undergo surgeries, including colectomies and colostomies.

Unfortunately, that treatment consists of taking medications that do little to stop the pain, much less cure the underlying disease. And the cost of treatment is astronomical. Patients currently spend a mind-boggling $8.5 billion on IBD drugs each year. And that’s forecast to grow to $9.5 billion by 2020. (6)

Ending Superbug Infections

Vitality BioPharma (VBIO) also has their drug “VXB-210” in studies for the treatment of so-called “superbug” infections caused by an extremely nasty bacterium called Clostridium difficile (klos-TRID-e-um dif-uh-SEEL). C. difficile is both extremely virulent and extremely difficult to kill. It affects an estimated half million Americans each year, causing symptoms ranging from diarrhea to life-threatening inflammation of the colon. (7)

In a press release dated May 10, 2017, VBIO announced that it had filed for patent protection on the use of one of its cannabosides (presumably VXB-210) for the treatment of infections caused by Clostridium difficile and other ‘superbug’ pathogens.

There are half a dozen current treatment options for C. difficile infections, ranging in cost from $1,300 to $2,600. Assuming an average cost of $2,000 and half a million cases a year (in the U.S. alone), we’re looking at an annual market worth half a billion dollars ($500,000,000). (8)

Globally Vitality BioPharma is poised to quickly take market share out of that industry!

Attacking Colon Cancer Cells

The company has also announced the results of pre-clinical studies showing that one of its cannabosides is effective in the treatment of “multiple colon cancer cell types". 

According to the American Cancer Society, colon cancer kills over 50,000 people in the U.S. every year, making it the third leading cause of cancer-related death. (9)

The National Institute of Health estimates that treatment costs will reach $17.4 billion within the next two years. (10) 

Again, securing just 10% of this market, would provide the company with $1.7 billion of annual revenue.

The List Continues to GROW

As of publication, Vitality BioPharma (VBIO) has identified and obtained protection for almost 200 cannabinoid/glycoside combinations that appear to have medicinal value. Only about 20 of those, thus far, have been used to create actual drugs.

There’s so much research in the pipeline that the amount of drugs that VBIO could bring to market may be in the HUNDREDS.

The company could be a named mentioned with Pitzer, Perdue, and Johnson & Johnson. A GLOBAL player that came about from their research that’s leading towards the solution to problems for millions of patients, and solving the problem that the FDA and DEA had with the entire medical marijuana industry!

The Team Leading The Movement

In my recently published ebook, I list several key factors that helped medical stocks explode...one of the biggest was the TEAM behind the company. The leadership, research, and depth are factors about which investors take note. Vitality BioPharma’s team (below) have this “it” factor.

10 Keys For Massive Success (History Lesson)

In my 25 years of trading and research I’ve discovered that there are 10 KEYS to massive stock success...short term and long term. These I cover in my ebook, but suffice it to say that when they ALL align then the market truly has the potential to deliver a trading opportunity like none other.

UPDATE: VBIO has hit ALL 10 KEYS...

  • Market Potential
  • Experienced Management
  • Pivot Start-up
  • Pipeline
  • Elasticity
  • Orphan Drug Designation
  • Scientific Stability
  • Prodrugs
  • Patent and Process Protection 
  • Phase 2 & 3 Winners

But what’s so captivating about VBIO is that it doesn’t just have one, or a couple of these key factors, it brings home all 10!!! Potentially making VBIO the medical stock game changer on the market right now. Frankly, if society didn’t still have to deal with the past stigma of using CBD/THC in the medical field, cannabinoids would be heralded as the biggest medical breakthrough of this generation. VBIO has met both of these challenges and changed the whole dynamic of the industry by unlocking the medicinal potential of CBD, while eliminating all the negative side effects.

Having all 10 of these key factors locks-in mega profit potential for investors. VB100 & VB210 has been shown to treat a multitude of illnesses and has shown to be a safe alternative and more effective than other treatments currently available. They are leading the industry developing new compounds and protecting their IP. Knowing all this takes research and industrial knowledge that takes time to consume and mentally digest. However, one thing an investor cannot control is time. When is the best time to invest in a biopharma company? What has happened over time?

This is what makes VBIO’s cannabinoid pharmaceuticals unique and sets them apart from every other CBD pharma on the market or currently undergoing clinical trials. VBIO holds the patents to their own compounds and has continued to show increased safety and efficacy upon entering phase II trials with VB210 and VB100 in 2018.

And as the market continues to change we will see more and more Cannabis products and services try to make a dent in the medical niche...the issue they will face is timing.

First and BEST to market often dominate.

The rest are just picking up scraps.

Don’t forget to follow the 10 Keys For Massive Success, laid out in my new ebook, that will help you discover for yourself how to make wise investments in the pharma/biotech niche.

6. Global Inflammatory Bowel Diseases (IBD) Drug Market Forecast 2017-2027; retrieved electronically from https://www.visiongain.com/Report/1830/Global-Inflammatory-Bowel-Diseases-(IBD)-Drug-Mark et-Forecast-2017-2027

7. https://www.mayoclinic.org/diseases-conditions/c-difficile/symptoms-causes/syc-20351691

8. Lutz, R. What is the Most Cost Effective C. difficile Treatment? MD Magazine. Retrieved electronically from http://www.mdmag.com/medical-news/what-is-the-most-cost-effective-c-difficile-treatment

9. https://www.cancer.org/cancer/colon-rectal-cancer/about/key-statistics.html

10. National Institute of Health cost projection for 2020 retrieved electronically from https://costprojections.cancer.gov/expenditures.html

The Complete Guide To Identifying Record-Breaking Trades.

Thank You! Your Ebook Is READY!

Start Reading “The Complete Guide to Identifying Record-Breaking Trades”

You’ve taken a GREAT first step towards some amazing trading opportunities and I’m so grateful that you’ve given me the chance to share MY knowledge with YOU!

Daryl Thompson


Learn to Find and Trade The Simple Keys That Record-Breaking Stocks Have In Common For Major Profits

The Complete Guide To Identifying Record-Breaking Trades.

Thank You! Your Ebook Is READY!

Start Reading “The Complete Guide to Identifying Record-Breaking Trades”

You’ve taken a GREAT first step towards some amazing trading opportunities and I’m so grateful that you’ve given me the chance to share MY knowledge with YOU!

Daryl Thompson


Learn to Find and Trade The Simple Keys That Record-Breaking Stocks Have In Common For Major Profits

ADVERTISEMENT DISCLAIMER

THIS REPORT/ADVERTORIAL (“ADVERTORIAL”) IS A PAID COMMERCIAL ADVERTISEMENT AND IS FOR GENERAL INFORMATION PURPOSES ONLY. Neither The Trading Letter nor Daryl Thompson (“Endorser) is making a recommendation that the securities of the companies profiled or discussed on this website should be purchased, sold or held by readers that learn of the profiled companies through this website. This Advertorial was paid for by a non-issuer third party in an effort to enhance public awareness of Vitality BioPharma (VBIO) and its securities. TheTradingLetter.com has or will receive $30,000 in cash in connection with this effort. Endorser has or will receive compensation in the form of leads valued at approximately $1,000 that are expected to result in additional subscription revenue in connection with this effort. Neither TheTradingLetter.com nor Endorser currently holds the securities of VBIO and do not currently intend to purchase such securities. Endorser is solely responsible for and has ultimate authority over the Advertorial and contents of the statements contained in this Advertorial. This Advertorial is based exclusively on information generally available to the public and does not contain any material, non-public information. Neither TheTradingLetter.com nor Endorser warrants the accuracy of such information. Certain statements contained in this Advertorial may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. Forward-looking statements often include words such as "believes," "anticipates," "estimates," “expects," "projects,” “intends,” or other similar expressions of future performance or conduct. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made and are not statements of historical fact. They involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. There is no guarantee that past performance will be indicative of future results. Neither TheTradingLetter.com nor Endorser undertakes an obligation to update forward-looking statements in light of new information or future events. Readers can review all public SEC filings made by the featured company at https://www.sec.gov/edgar/searchedgar/companysearch.html.

Neither TheTradingLetter.com nor Endorser are licensed in the securities industry in any manner. Please review all investment decisions with a licensed investment advisor.